Form 4 for CLYM Climb Bio, Inc.
Accepted 2024-06-27 00:00:00 ET · period of report 2024-06-27 · accession 0000950170-24-078685 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-06-27 | 2024-06-27 | CLYM | Thomas Stephen Basil | Dir | A - Grant | — | +103.9K | 103.9K | New | — |
| D | 2024-06-27 | 2024-06-27 | CLYM | Thomas Stephen Basil | Dir | A - Grant | $0.00 | +100.4K | 100.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-06-27 | A | A | 103,907 | — | 103,907 | D | — | — | (F1) The Reporting Person acquired 103,907 shares of the issuer's common stock in exchange for 838,000 shares of common stock of Tenet Medicines, Inc. ("Tenet") in connection with the issuer's acquisition of all of the outstanding common stock of Tenet on June 27, 2024 (the "Acquisition"). On the effective date of the Acquisition, the closing price of the issuer's common stock was $7.53 per share. |
| 2 | Derivative | Restricted Stock Units | 2024-06-27 | A | A | 100,375 | $0.00 | 100,375 | D | — · — to — | 100,375 Common Stock | (F2) Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon vesting. (F3) The RSUs were granted on June 27, 2024 and will vest as to 50% of the shares on January 1, 2025, as to 25% of the shares on March 27, 2025 and as to the remaining 25% of the shares on June 27, 2025, subject to the Reporting Person's continued service. |